Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314200 | 0.86 | NR4A2 (0.56) | NR4A2SOS2NOS3NOS2NCF1 | |
| SCHEMBL30174440 | 0.80 | ADRB2 (0.52) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL18582354 | 0.80 | ADRB2 (0.52) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL22854 | 0.80 | ADRB2 (0.52) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL2201230 | 0.80 | ADRB2 (0.52) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL31121093 | 0.80 | ADRB2 (0.52) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL2345433 | 0.79 | ADRB2 (0.51) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL31312344 | 0.79 | ADRB2 (0.51) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL18535272 | 0.79 | ADRB2 (0.51) | NOS3NOS2NCF1ADRB2PARP1 | |
| SCHEMBL9829215 | 0.79 | ADRB2 (0.51) | NOS3NOS2NCF1ADRB2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017180769-A1 | SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER | CAPTEN THERAPEUTICS INC. (US) | 2017-10-19 | — | — | WO | claimed |
| CN-114773267-B | [ (7-trifluoromethyl quinoline-4-yl) amino ] benzamide compound and preparation and application thereof | 沈阳药科大学 | 2024-01-26 | — | — | CN | disclosed |
| EP-3351543-A1 | 1-(QUINOLIN-4-YL)-3-(6-(TRIFLUOROMETHYL)-PYRIDIN-2-YL)UREA AND 1-(QUINOLIN-4-YL)-3-(6-(TRIFLUOROMETHYL)-PYRAZINE-2-YL)UREA DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-9856234-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| WO-2017180769-A1 | SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER | CAPTEN THERAPEUTICS INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9090592-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8642598-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-1844038-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1675850-A1 | QUINOLINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| US-20050113412-A1 | Quinoline compounds and their uses | MIDCAP FINANCIAL TRUST | 2005-05-26 | — | — | US | disclosed |
| WO-2005033103-A1 | QUINOLINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | NR4A2 421/4885SOS2 1887/4885NOS3 3638/4885 |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | NR4A2 4206/4885SOS2 1410/4885NOS3 1177/4885 |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | NR4A2 3713/4885SOS2 1646/4885NOS3 1671/4885 |
| US-20050113412-A1 | Quinoline compounds and their uses | MRGPRX1, MRGPRX2, HRH4 | NR4A2 463/4885SOS2 3556/4885NOS3 709/4885 |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | RB1, ALDH1A2, CDK4 | NR4A2 721/4885SOS2 2039/4885NOS3 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.